At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof of Concept Study to Evaluate Differential Tachyphylaxis of Alpha 1 and Alpha 2 Adrenoreceptor Mediated Decongestant Response to Oxymetazoline and Its Acute Reversal by Corticosteroid in Healthy Volunteers
In Brief
A Phase 4 clinical trial evaluating Oxymetazoline 0.05% w/v, Fluticasone propionate 50 micrograms per actuation, and 2 other interventions for Allergic Rhinitis and 2 related conditions. Completed, enrolled 19 participants across 2 sites.
Detailed Summary
The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
Study Details
Timeline
Interventions
2 squirts in each nostril thrice daily
2 Squirts in each nostril twice daily
Prazosin 1mg one dose only
Placebo 1 tablet one dose only